Cancer stem cells as therapeutic targets of pancreatic cancer.
cancer stem cell
pancreatic cancer
therapeutic targets
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
05
02
2019
revised:
02
11
2019
accepted:
06
11
2019
pubmed:
12
11
2019
medline:
26
11
2020
entrez:
12
11
2019
Statut:
ppublish
Résumé
The discovery of stem cells and their potential abilities in self-renewal and differentiation has opened a new horizon in medicine. Scientists have found a small population of stem cells in some types of cancers with the same functions as normal stem cells. There are two models for tumor progression: clonal (stochastic) and cancer stem cell (CSCs) models. According to the first model, all transformed cells in the tumor have carcinogenic potential and are able to proliferate and produce the same cells. The latter model, which has received more attention recently, considers the role of CSCs in drug resistance and tumor metastasis. Following the model, researchers have found that targeting CSCs may be a promising way in cancer therapy. This review describes CSC characteristics in general, while also focusing on CSC properties in the context of pancreatic cancer.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
202-212Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Société Française de Pharmacologie et de Thérapeutique.
Références
Pourhanifeh M.H., Mohammadi R., Noruzi S. et al. The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy. Cancer Cell Int. (2019) 19 157. https://doi.org/10.1186/s12935-019-0870-6
Mirzaei H.R., Pourghadamyari H., Rahmati M. et al. Gene-knocked out chimeric antigen receptor (CAR) T cells: tuning up for the next generation cancer immunotherapy. Cancer Lett. (2018) 423 95-104.
Mohammadi M., Jaafari M.R., Mirzaei H.R., Mirzaei H. Mesenchymal stem cell: a new horizon in cancer gene therapy. Cancer Gene Ther. (2016) 23 285-286.
Saadatpour Z., Rezaei A., Ebrahimnejad H. et al. Imaging techniques: new avenues in cancer gene and cell therapy. Cancer Gene Ther. (2017) 24 1-5.
Saadatpour Z., Bjorklund G., Chirumbolo S. et al. Molecular imaging and cancer gene therapy. Cancer Gene Ther. (2016). https://doi.org/10.1038/cgt.2016.62. in press
Adorno-Cruz V., Kibria G., Liu X. et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. (2015) 75 924-929.
Mirzaei H.R., Sahebkar A., Salehi R. et al. Boron neutron capture therapy: moving toward targeted cancer therapy. J. Cancer Res. Ther. (2016) 12 520-525.
Mirzaei H.R., Mirzaei H., Lee S.Y., Hadjati J., Till B.G. Prospects for chimeric antigen receptor (CAR) gammadelta T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. (2016) 380 413-423.
Mirzaei H., Sahebkar A., Jaafari M.R. et al. PiggyBac as a novel vector in cancer gene therapy: current perspective. Cancer Gene Ther. (2016) 23 45-47.
Zabala M., Lobo N., Qian D. et al. Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res (2015) 75 924-929. https://doi.org/10.1158/0008-5472.CAN-14-3225.
Mirzaei H., Sahebkar A., Sichani L.S. et al. Therapeutic application of multipotent stem cells. J. Cell Physiol. (2018) 233 2815-2823.
Mirzaei H., Sahebkar A., Avan A. et al. Application of mesenchymal stem cells in melanoma: a potential therapeutic strategy for delivery of targeted agents. Curr. Med. Chem. (2016) 23 455-463.
Mirzaei H., Salehi H., Oskuee R.K. et al. The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model. Cancer Lett. (2018) 419 30-39.
Goradel N.H., Hour F.G., Negahdari B. et al. Stem cell therapy: a new therapeutic option for cardiovascular diseases. J. Cell Biochem. (2018) 119 95-104.
Yu Z., Pestell T.G., Lisanti M.P., Pestell R.G. Cancer stem cells. Int. J. Biochem. Cell Biol. (2012) 44 2144-2151.
Gharagozloo M., Mirzaei H.R., Bagherpour B. et al. Cell cycle analysis of the CD133(+) and CD133(−) cells isolated from human colorectal cancer. J. Cancer Res. Ther. (2012) 8 399-403.
Mirzaei H., Salehi H., Sahebkar A. et al. Deciphering biological characteristics of tumorigenic subpopulations in human colorectal cancer reveals cellular plasticity. J Res Med Sci. (2016) 21 1735-995.
O'Connor M.L., Xiang D., Shigdar S. et al. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett. (2014) 344 180-187.
Chen K., Huang Y.-H., Chen J.-L. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol. Sin. (2013) 34 732-740. https://doi.org/10.1038/aps.2013.27
Cheng B., Yang G., Jiang R. et al. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis. Oncotarget. (2016) 7 65862-65875.
Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem Cell (2014) 14 275-291.
Dragu D.L., Necula L.G., Bleotu C., Diaconu C.C., Chivu-EconomescuM. Therapies targeting cancer stem cells: current trends and future challenges. World J. Stem Cells (2015) 7 1185-1201.
Cherciu I., Bărbălan A., Pirici D., Mărgăritescu C., Săftoiu A. Stem cells, colorectal cancer and cancer stem cell markers correlations. Curr. Health Sci. J. (2014) 40 153-161.
Reid P., Marcu L.G., Olver I., Moghaddasi L., Staudacher A.H., Bezak E. Diversity of cancer stem cells in head and neck carcinomas: the role of HPV in cancer stem cell heterogeneity, plasticity and treatment response. Radiother. Oncol. (2019) 135 1-12.
Reid P.A., Wilson P., Li Y., Marcu L.G., Bezak E. Current understanding of cancer stem cells: review of their radiobiology and role in head and neck cancers. Head Neck (2017) 39 1920-1932.
Plaks V., Kong N., Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell (2015) 16 225-238.
Miekus K. The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance (Review). Oncol. Rep. (2017) 37 647-656.
Boumahdi S., Driessens G., Lapouge G. et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature (2014) 511 246-250.
Han L., Shi S., Gong T., Zhang Z., Sun X..Cancer stem cells: therapeutic implications and perspectives in cancer therapy. Acta Pharmaceutica Sinica B (2013) 3 65-75.
Zhang S., Mercado-Uribe I., Xing Z., Sun B., Kuang J., Liu J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene (2014) 33 116-128.
Pattabiraman D.R., Weinberg R.A. Tackling the cancer stem cells-what challenges do they pose? Nat. Rev. Drug Discov. (2014) 13 497-512.
Trumpp A., Baccelli I. Biology of cancer and metastasis stem cells. Oxford Textbook of. Annu Rev Cell Dev Biol (2007) 23 675-699.
Abbaszadegan M.R., Bagheri V., Razavi M.S., Momtazi A.A., Sahebkar A., Gholamin M. Isolation, identification, and characterization of cancer stem cells: a review. J. Cell. Physiol. (2017) 232 2008-2018.
Vidal S., Rodriguez-Bravo V., Galsky M., Cordon-Cardo C., Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene (2014) 33 4451-4463.
Allegra A., Alonci A., Penna G. et al. The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Invest. (2014) 32 470-495.
Rahman M., Jamil H.M., Akhtar N., Rahman K., Islam R., Asaduzzaman S. Stem cell and cancer stem cell: a tale of two cells. Progress Stem Cell (2016) 3 97-108.
Taylor N.M.I., Manolaridis I., Jackson S.M., Kowal J., Stahlberg H., Locher K.P. Structure of the human multidrug transporter ABCG2. Nature (2017) 546 504-509.
Rane J.K., Scaravilli M., Ylipää A. et al. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur. Urol. (2015) 67 7-10.
Brower J.V., Clark P.A., Lyon W., Kuo J.S. MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells. Neurochem. Int. (2014) 77 68-77.
Singh R., Palanichamy K., Jacob J.R., Chakravarti A. Mir-194-3p suppresses tumorigenic potential of glioblastoma stem cells by targeting the canonical NF-kB pathway. In AACR, 2016.
Martínez-Jiménez V., Méndez-Mancilla A.,Portales-PérezD.P. miRNAs in nutrition, obesity and cancer: the biology of miRNAs in metabolic disorders and its relationship with cancer development. Mol. Nutr. Food Res. (2018) 62 https://doi.org/10.1002/mnfr.201600994
Paulson A.S., Cao H.S.T., Tempero M.A., Lowy A.M. Therapeutic advances in pancreatic cancer. Gastroenterology (2013) 144 1316-1326.
Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Can. Res. (2014) 74 2913-2921.
Jin X., Jin X., Kim H. Cancer stem cells and differentiation therapy. Tumour Biol. (2017) 39 1010428317729933.
Keane M.G., Bramis K., Pereira S.P., Fusai G.K. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J. Gastroenterol. (2014) 20 2267-2278.
Maisonneuve P., Lowenfels A.B. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int. J. Epidemiol. (2015) 44 186-198.
Chari S.T., Kelly K., Hollingsworth M.A. et al. Early detection of sporadic pancreatic cancer: summative review. Pancreas (2015) 44 693-712.
Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. (2016) 66 7-30.
Malvezzi M., Carioli G., Bertuccio P. et al. European cancer mortality predictions for the year 2016 with focus on leukemias. Ann. Oncol. (2016) 27 725-731.
Jung K.-W., Won Y.-J., Kong H.-J. et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res. Treat. (2015) 47 127-141.
Bruns C., Niess H., Schwarz B., Kleespies A., Angele M., Jauch K. What we know about carcinogenesis of ductal adenocarcinoma of the pancreas. In Pancreatic cancer, cystic neoplasms and endocrine tumors: diagnosis and management, 2015, p. 392.
Barbacid M. Abstract IA25: Targeting K-Ras signaling in pancreatic cancer, in AACR (2015).
Oshima M., Okano K., Muraki S. et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann. Surg. (2013) 258 336-346.
Golan T., Sella T., Javle M.M. et al. Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC). Br J Cancer. 2017; 116 697-702.
Oettle H., Riess H., Stieler J.M. et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J. Clin. Oncol. (2014) 32 2423-2429.
Von Hoff D.D., Ervin T., Arena F.P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. (2013) 369 1691-1703.
Oettle H., Neuhaus P., Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 310 1473-1481.
Egan A.G., Blind E., Dunder K. et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N. Engl. J. Med. (2014) 370 794-797.
Garrido-Laguna I., Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat. Rev. Clin. Oncol. (2015) 12 319-334.
Ahmed M., Chaudhari K., Babaei-Jadidi R., Dekker L.V., Shams NateriA. Concise review: emerging drugs targeting epithelial cancer stem-like cells. Stem Cells (2017) 35 839-850.
Singh D., Upadhyay G., Srivastava R.K., Shankar S. Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochem. Biophys. Acta.et Biophysica Acta (2015) 1856 13-27.
Tang S.-C., Chen Y.-C. Novel therapeutic targets for pancreatic cancer. World J. Gastroenterol. (2014) 20 10825-10844.
Shen C.-N., Hsieh C.-C., Li W.-S., Hsiao M. Therapeutic implication of identifying pancreatic cancer stem cells possessing fructose metabolic signature, in AACR (2016).
Pan Y., Ma S., Cao K. et al. Therapeutic approaches targeting cancer stem cells. J. Cancer Res. Ther. (2018) 14 1469-475.
Shabaninejad Z., Vafadar A., Movahedpour A. et al. Circular RNAs in cancer: new insights into functions and implications in ovarian cancer. J. Ovarian Res. (2019) 12 84.
Vafadar A., Shabaninejad Z., Movahedpour A. et al. Long non-coding RNAs: epigenetic regulators in cancer. Curr. Pharm. Des. (2019). https://doi.org/1381612825666190830161528.
Shabaninejad Z., Yousefi F., Movahedpour A. et al. Electrochemical-based biosensors for microRNA detection: nanotechnology comes into view. Anal Biochem. (2019) 581 113349. https://doi.org/10.1016/j.ab.2019.113349.
Toh T.B., Lim J.J., Chow E.K. Epigenetics in cancer stem cells. Mol Cancer. (2017) 16 017-0596.
Jafari Najaf Abadi M.H., Shafabakhsh R., Asemi Z. et al. CFIm25 and alternative polyadenylation: conflicting roles in cancer. Cancer Lett. (2019) 459 112-21.
Mirzaei H., Yazdi F., Salehi R., Mirzaei H.R. SiRNA and epigenetic aberrations in ovarian cancer. J. Cancer Res. Ther. (2016) 12 498-508.
Naeli P., Yousefi F., Ghasemi Y., Savardashtaki A., Mirzaei H. The role of microRNAs in Lung Cancer: Implications for diagnosis and therapy. Curr. Mol. Med. (2019). https://doi.org/10.2174/1566524019666191001113511
Javandoost E., Majd E.F., Rostamian H., Koosheh M.K., Mirzaei H.R. Role of microRNAs in chronic lymphocytic leukemia pathogenesis. Curr. Med. Chem. (2019). https://doi.org/10.2174/0929867326666190911114842
Gholamin S., Mirzaei H., Razavi S.M. et al. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. J. Cell Physiol. (2018) 233 866-879.
Moridikia A., Mirzaei H., Sahebkar A., Salimian J. MicroRNAs: potential candidates for diagnosis and treatment of colorectal cancer. J. Cell Physiol. (2018) 233 901-913.
Salarinia R., Sahebkar A., Peyvandi M. et al. Epi-drugs and Epi-miRs: moving beyond current cancer therapies. Curr. Cancer Drug Targets (2016) 16 773-788.
Mirzaei H., Khataminfar S., Mohammadparast S. et al. Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in gastric cancer: current status and future perspectives. Curr. Med. Chem. (2016) 23 4135-4150.
Mirzaei H.R., Sahebkar A., Mohammadi M. et al. Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers. Curr. Pharm. Des. (2016) 22 5257-5269.
Mirzaei H., Gholamin S., Shahidsales S. et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur. J. Cancer (2016) 53 25-32.
Golabchi K., Soleimani-Jelodar R., Aghadoost N. et al. MicroRNAs in retinoblastoma: potential diagnostic and therapeutic biomarkers. J. Cell Physiol. (2018) 233 3016-3023.
Keshavarzi M., Sorayayi S., Jafar Rezaei M. et al. MicroRNAs-based imaging techniques in cancer diagnosis and therapy. J. Cell Biochem. (2017) 118 4121-4128.
Mirzaei H., Fathullahzadeh S., Khanmohammadi R. et al. State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. J. Cell Physiol. (2018) 233 888-900.
Mirzaei H., Sahebkar A., Jaafari M.R., Goodarzi M., Mirzaei H.R. Diagnostic and therapeutic potential of exosomes in cancer: the beginning of a new tale? J. Cell Physiol. (2017) 232 3251-3260.
Pakshir K., Badali H. Interactions between immune response to fungal infection and microRNAs; the pioneer tuners. Mycoses (2019) 13017. in press.
Pakshir K., Badali H., Nami S., Mirzaei H., Ebrahimzadeh V., Morovati H. Interactions between immune response to fungal infection and microRNAs; the pioneer tuners. Mycoses (2019) 13017. in press.
Nahand J.S., Taghizadeh-Boroujeni S., Karimzadeh M. et al. microRNAs: new prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. J. Cell Physiol. (2019) 234 17064-17099.
Masoudi M.S., Mehrabian E., Mirzaei H. MiR-21: a key player in glioblastoma pathogenesis. J. Cell Biochem. (2018) 119 1285-1290.
Mashreghi M., Azarpara H., Bazaz M.R. et al. Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. J. Cell Physiol. (2018) 233 2949-2965.
Hashemi GoradelN., Ghiyami-Hour F. et al. Nanoparticles as new tools for inhibition of cancer angiogenesis. J. Cell Physiol. (2018) 233 2902-2910.
Hoseini Z., Sepahvand F., Rashidi B., Sahebkar A., Masoudifar A., Mirzaei H. NLRP3 inflammasome: its regulation and involvement in atherosclerosis. J. Cell Physiol. (2018) 233 2116-2132.
Rashidi B., Malekzadeh M., Goodarzi M., Masoudifar A., Mirzaei H. Green tea and its anti-angiogenesis effects. Biomed. Pharmacother. (2017) 89 949-956.
Sadri NahandJ., Moghoofei M. et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review. Int. J. Cancer. (2019) 30 32688. in press.
Saeedi Borujeni M.J., Esfandiary E., Baradaran A. et al. Molecular aspects of pancreatic beta-cell dysfunction: oxidative stress, microRNA, and long noncoding RNA. J. Cell Physiol. (2019) 234 8411-8425.
Khani P., Nasri F., Khani Chamani F. et al. Genetic and epigenetic contribution to astrocytic gliomas pathogenesis. J. Neurochem. (2019) 148 188-203.
Tavakolizadeh J., Roshanaei K., Salmaninejad A. et al. MicroRNAs and exosomes in depression: potential diagnostic biomarkers. J. Cell Biochem. (2018) 119 3783-3797.
Mirzaei H., Ferns G.A., Avan A., Mobarhan M.G. Cytokines and MicroRNA in coronary artery disease. Adv. Clin. Chem. (2017) 82 47-70.
Saeedi Borujeni M.J., Esfandiary E., Taheripak G., Codoner-Franch P., Alonso-Iglesias E., Mirzaei H. Molecular aspects of diabetes mellitus: Resistin, microRNA, and exosome. J. Cell Biochem. (2018) 119 1257-1272.
Rabieian R., Boshtam M., Zareei M., Kouhpayeh S., Masoudifar A., Mirzaei H. Plasminogen activator inhibitor type-1 as a regulator of fibrosis. J. Cell Biochem. (2018) 119 17-27.
Mirzaei H., Momeni F., Saadatpour L. et al. MicroRNA: Relevance to stroke diagnosis, prognosis, and therapy. J. Cell Physiol. (2018) 233 856-865.
Rashidi B., Hoseini Z., Sahebkar A., Mirzaei H. Anti-atherosclerotic effects of vitamins D and E in suppression of atherogenesis. J. Cell Physiol. (2017) 232 2968-2976.
Keshavarz M., Mirzaei H., Salemi M. et al. Influenza vaccine: where are we and where do we go? Rev. Med. Virol. (2019) 29 e2014.
Mirzaei H.R., Mirzaei H., Namdar A., Rahmati M., Till B.G., Hadjati J. Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: a clinical perspective. J. Cell Physiol. (2019) 234 5827-5841.
Jamali L., Tofigh R., Tutunchi S. et al. Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J. Cell Physiol. (2018) 233 8538-8550.
Simonian M., Mosallayi M., Mirzaei H. Circulating miR-21 as novel biomarker in gastric cancer: diagnostic and prognostic biomarker. J. Cancer Res. Ther. (2018) 14 475.
Jafari S.H., Saadatpour Z., Salmaninejad A. et al. Breast cancer diagnosis: imaging techniques and biochemical markers. J. Cell Physiol. (2018) 233 5200-5213.
Mirzaei H. Stroke in women: risk factors and clinical biomarkers. J. Cell Biochem. (2017) 118 4191-4202.
Keshavarzi M., Darijani M., Momeni F. et al. Molecular imaging and oral cancer diagnosis and therapy. J. Cell Biochem. (2017) 118 3055-3060.
Saadatpour L., Fadaee E., Fadaei S. et al. Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther. (2016) 23 415-418.
Fathullahzadeh S., Mirzaei H., Honardoost M.A., Sahebkar A., Salehi M. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther. (2016) 23 327-332.
Mohammadi M., Goodarzi M., Jaafari M.R., Mirzaei H.R., Mirzaei H. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther. (2016) 23 371-372.
Xu Y.F., Hannafon B.N., Ding W.Q. microRNA regulation of human pancreatic cancer stem cells. Stem Cell Investig. (2017) 4 5. https://doi.org/10.21037/sci.2017.01.01
Bao B., Wang Z., Ali S. et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev. Res. (2012) 5 355-364.
Ma C., Ding Y.C., Yu W., Wang Q., Meng B., Huang T. MicroRNA-200c overexpression plays an inhibitory role in human pancreatic cancer stem cells by regulating epithelial-mesenchymal transition. Minerva Med. (2015) 106 193-202.
Park S.H., Sung J.H., Chung N. Berberine diminishes side population and down-regulates stem cell-associated genes in the pancreatic cancer cell lines PANC-1 and MIA PaCa-2. Mol. Cell. Biochem. (2014) 394 209-215.
Chung S.S., Vadgama J.V. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFkappaB signaling. Anticancer Res. (2015) 35 39-46.
Ahmed S., Khan H., Mirzaei H. Mechanics insights of curcumin in myocardial ischemia: where are we standing? Eur. J. Med. Chem. (2019) 183 111658.
Ghasemi F., Shafiee M., Banikazemi Z. et al. Curcumin inhibits NF-kB and Wnt/beta-catenin pathways in cervical cancer cells. Pathol. Res. Pract. (2019) 215 152556.
Shafabakhsh R., Pourhanifeh M.H., Mirzaei H.R., Sahebkar A., Asemi Z., Mirzaei H. Targeting regulatory T cells by curcumin: a potential for cancer immunotherapy. Pharmacol. Res. (2019) 147 104353.
Hesari A., Azizian M., Sheikhi A. et al. Chemopreventive and therapeutic potential of curcumin in esophageal cancer: current and future status. Int. J. Cancer (2019) 144 1215-1226.
Banikazemi Z., Haji H.A., Mohammadi M. et al. Diet and cancer prevention: dietary compounds, dietary MicroRNAs, and dietary exosomes. J. Cell Biochem. (2018) 119 185-196.
Mirzaei H., Masoudifar A., Sahebkar A. et al. MicroRNA: a novel target of curcumin in cancer therapy. J. Cell. Physiol. (2018) 233 3004-15.
Mirzaei H., Shakeri A., Rashidi B., Jalili A., Banikazemi Z., Sahebkar A. Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed. Pharmacother. (2017) 85 102-112.
Mirzaei H., Khoi M.J., Azizi M., Goodarzi M. Can curcumin and its analogs be a new treatment option in cancer therapy? Cancer Gene Ther. (2016) 23 410.
Mirzaei H., Naseri G., Rezaee R. et al. Curcumin: a new candidate for melanoma therapy? Int. J. Cancer (2016) 139 1683-1695.
Sadeghi S., Davoodvandi A., Pourhanifeh M.H. et al. Anti-cancer effects of cinnamon: insights into its apoptosis effects. Eur. J. Med. Chem. (2019) 178 131-140.
Fitzgerald T.L., McCubrey J.A. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Adv. Biol. Regul. (2014) 56 45-50.
Li Y., Kong D., Ahmad A., Bao B., Sarkar F.H. Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett. (2013) 338 94-100.
Subramaniam D., Kaushik G., Dandawate P., Anant S. Targeting cancer stem cells for chemoprevention of pancreatic cancer. Curr. Med. Chem. (2018). 25 2585-2594.
Yin T., Shi P., Gou S., Shen Q., Wang C. Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro. PLoS ONE (2014) 9 e114581.
Li C., Heidt D.G., Dalerba P. et al. Identification of pancreatic cancer stem cells. Can. Res. (2007) 67 1030-1037.
Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Can. Res. (2005) 65 10946-10951.
Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. (2006) 5 483-493.
White B.D., Chien A.J., Dawson D.W. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology (2012) 142 219-232.
Koshiba T., Hosotani R., Miyamoto Y. et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. (2000) 6 3530-3535.
Alison M.R., Lin W.-R., Lim S.M., Nicholson L.J. Cancer stem cells: in the line of fire. Cancer Treat. Rev. (2012) 38 589-598.
Suzuki S., Okada M., Shibuya K. et al. JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget. (2015) 6 458-470.
Zhang Y., Liu L., Fan P. et al. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Oncotarget. (2015) 6 9999-10015.
Wolpin B.M., Hezel A.F., Abrams T. et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. (2009) 27 193-198.
Bruns C.J., Koehl G.E., Guba M. et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin. Cancer Res. (2004) 10 2109-2119.
Schneider M.B., Matsuzaki H., Haorah J. et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology (2001) 120 1263-1270.
Melstrom L.G., Salabat M.R., Ding X.-Z. et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas (2008) 37 426-431.
Marks P., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. (2009) 107 600-608.
Crowder S.W., Liang Y., Rath R. et al. Poly(epsilon-caprolactone)-carbon nanotube composite scaffolds for enhanced cardiac differentiation of human mesenchymal stem cells. Nanomedicine (2013) 8 1763-1776.
Siu L.L., Awada A., Takimoto C.H. et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. (2006) 12 144-151.
Ströhlein M.A., Lordick F., Rüttinger D. et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Oncol Res Treat. (2011) 34 101-108.
Ivanovska I., Ball A.S., Diaz R.L. et al. MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol. Cell. Biol. (2008) 28 2167-2174.
Athar M., Back J.H., Tang X. et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. (2007) 224 274-283.
Lee D., Kim D., Choi Y.B. et al. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. mAbs (2016) 8 892-904.
Huang J., Li C., Wang Y. et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin. Immunol. (2013) 149 156-168.
Cao K., Pan Y., Yu L. et al. Monoclonal antibodies targeting non-small cell lung cancer stem-like cells by multipotent cancer stem cell monoclonal antibody library. Int. J. Oncol. (2017) 50 587-596.
Chen P., Huang H., Wu J. et al. Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis. Mol. Carcinog. (2015) 54 1678-1685.
Yang Z.X., Sun Y.H., He J.G., Cao H., Jiang G.Q. Increased activity of CHK enhances the radioresistance of MCF-7 breast cancer stem cells. Oncol. Lett. (2015) 10 3443-3449.
Li L., Hao X., Qin J. et al. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology (2014) 146 1108-1118.
Masuko K., Okazaki S., Satoh M. et al. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS ONE (2012) 7 e29728.
Siddikuzzaman B.G.V. Evaluation of immunomodulatory and antitumor activity of all trans retinoic acid (ATRA) in solid tumor bearing mice. Immunopharmacol. Immunotoxicol. (2013) 35 110-118.
Ranieri G., Gadaleta-Caldarola G., Goffredo V. et al. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr. Med. Chem. (2012) 19 938-944.
Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. (2007) 6 734-745.
Pal D., Kolluru V., Chandrasekaran B. et al. Targeting aberrant expression of Notch-1 in ALDH(+) cancer stem cells in breast cancer. Mol. Carcinog. (2017) 56 1127-1136.
Ferguson P.J., Vincent M.D., Koropatnick J. Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein. J. Pharmacol. Exp. Ther. (2018) 364 46-54.
Zhong Q., Liu Z.H., Lin Z.R. et al. The RARS-MAD1L1 fusion gene induces cancer stem cell-like properties and therapeutic resistance in nasopharyngeal carcinoma. Clin. Cancer Res. (2018) 24 659-673.
Kubota K., Yoshioka H., Oshita F. et al. Phase III, randomized, placebo-controlled, double-blind trial of motesanib (AMG-706) in combination with paclitaxel and carboplatin in East Asian patients with advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. (2017) 35 3662-3670.
Gonzalez-Gomez P., Crecente-Campo J., Zahonero C. et al. Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma. Oncotarget. (2015) 6 10950-10963.
Schmoch T., Gal Z., Mock A. et al. Combined treatment of ATRA with epigenetic drugs increases aggressiveness of glioma xenografts. Anticancer Res. (2016) 36 1489-1496.